Bristol-myers Squibb Stock Earnings Reports

Bristol-Myers Squibb reported a solid start to 2026 with Q1 revenue of ~$11.5B (up 1% YoY) and a 9% increase in the growth portfolio to $6.2B. Key marketed performers included Eliquis (13% growth), Breyanzi (53% growth), Reblozyl (15% growth), Camzyos (~2x revenue YoY to $314M), and Sotyktu (20% growth). The company reiterated full-year 2026 guidance and said results are tracking toward the upper end of its ranges. R&D progress was highlighted across several programs: the iberdomide filing in relapsed/refractory multiple myeloma was accepted by the FDA with breakthrough designation and priority review (PDUFA date noted for August), positive pivotal/Phase III interim readouts for mezignomide (SUCCESSR-II) and an ADC in China, and multiple late-year pivotal readouts expected (including milvexian in AFib and secondary stroke prevention, Cobenfy in Alzheimer’s psychosis, and additional CELMoD data). Management emphasized efforts to boost R&D productivity (faster lead identification, AI and automation, and a target to reduce cycle times ~30%), continued cost discipline (aiming to deliver the remaining $2B of strategic productivity savings by end of 2027), and a balanced capital allocation approach that keeps business development a priority while returning cash to shareholders. Commercial strategy highlights include life-cycle expansions, multiple shots on goal for Cobenfy in AD psychosis and other CNS indications, and an assertive commercialization plan for cell- and gene-related immunology programs. Management expressed confidence in several late-stage programs (notably milvexian and admilparant) and reiterated readiness to pursue BD opportunities that align with strategic priorities.